Notice: This company has been marked as potentially delisted and may not be actively trading. BioTelemetry (BEAT) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends BEAT vs. IMAC, ANIK, LUNG, UTMD, CATX, OBIO, INFU, SGHT, ARAY, and PROFShould you be buying BioTelemetry stock or one of its competitors? The main competitors of BioTelemetry include IMAC (IMAC), Anika Therapeutics (ANIK), Pulmonx (LUNG), Utah Medical Products (UTMD), Perspective Therapeutics (CATX), Orchestra BioMed (OBIO), InfuSystem (INFU), Sight Sciences (SGHT), Accuray (ARAY), and Profound Medical (PROF). These companies are all part of the "medical" sector. BioTelemetry vs. IMAC Anika Therapeutics Pulmonx Utah Medical Products Perspective Therapeutics Orchestra BioMed InfuSystem Sight Sciences Accuray Profound Medical BioTelemetry (NASDAQ:BEAT) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk. Which has stronger earnings and valuation, BEAT or IMAC? IMAC has higher revenue and earnings than BioTelemetry. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioTelemetryN/AN/A-$14.64M-$0.68-3.65IMAC$15.22M1.79-$10.54MN/AN/A Is BEAT or IMAC more profitable? BioTelemetry has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat BioTelemetry's return on equity.Company Net Margins Return on Equity Return on Assets BioTelemetryN/A -175.50% -154.96% IMAC -75.40%-52.17%-34.51% Do institutionals and insiders hold more shares of BEAT or IMAC? 7.8% of BioTelemetry shares are held by institutional investors. Comparatively, 24.3% of IMAC shares are held by institutional investors. 20.9% of BioTelemetry shares are held by insiders. Comparatively, 10.0% of IMAC shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in BEAT or IMAC? BioTelemetry received 320 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 63.37% of users gave BioTelemetry an outperform vote while only 60.17% of users gave IMAC an outperform vote. CompanyUnderperformOutperformBioTelemetryOutperform Votes39163.37% Underperform Votes22636.63% IMACOutperform Votes7160.17% Underperform Votes4739.83% Which has more risk & volatility, BEAT or IMAC? BioTelemetry has a beta of -0.98, indicating that its stock price is 198% less volatile than the S&P 500. Comparatively, IMAC has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500. Does the media refer more to BEAT or IMAC? In the previous week, IMAC had 7 more articles in the media than BioTelemetry. MarketBeat recorded 7 mentions for IMAC and 0 mentions for BioTelemetry. IMAC's average media sentiment score of 0.26 beat BioTelemetry's score of 0.00 indicating that IMAC is being referred to more favorably in the news media. Company Overall Sentiment BioTelemetry Neutral IMAC Neutral Do analysts recommend BEAT or IMAC? BioTelemetry currently has a consensus target price of $8.00, suggesting a potential upside of 222.58%. Given BioTelemetry's stronger consensus rating and higher possible upside, equities research analysts plainly believe BioTelemetry is more favorable than IMAC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioTelemetry 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryIMAC beats BioTelemetry on 8 of the 15 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get BioTelemetry News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAT vs. The Competition Export to ExcelMetricBioTelemetrySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.14M$4.48B$5.10B$8.84BDividend YieldN/A36.79%5.04%4.07%P/E Ratio-3.6514.3295.1214.22Price / SalesN/A44.111,217.3088.42Price / CashN/A52.2739.4936.27Price / Book13.785.836.976.37Net Income-$14.64M$13.76M$118.73M$225.56M BioTelemetry Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEATBioTelemetry1.8598 of 5 stars$2.48-0.8%$8.00+222.6%+89.3%$66.14MN/A-3.651,700IMACIMACN/A$1.03+1.0%N/A-30.6%$27.28M$15.22M0.00106ANIKAnika Therapeutics2.8749 of 5 stars$17.54+2.1%$24.50+39.7%-16.6%$256.96M$166.66M-2.58357LUNGPulmonx2.5978 of 5 stars$6.30+1.6%$14.67+132.8%-42.9%$248.79M$68.68M0.00250UTMDUtah Medical Products3.4564 of 5 stars$64.05-0.2%N/A-23.5%$217.13M$50.22M15.03180Positive NewsCATXPerspective Therapeutics3.1686 of 5 stars$3.14-49.1%$21.57+587.0%N/A$212.23M$1.43M0.00116Analyst RevisionGap DownHigh Trading VolumeOBIOOrchestra BioMed2.4812 of 5 stars$5.40+2.3%$15.75+191.7%-21.7%$205.25M$2.76M0.0056Analyst RevisionINFUInfuSystem1.7031 of 5 stars$9.14+1.3%$13.00+42.2%N/A$194.32M$125.79M151.67499SGHTSight Sciences2.5293 of 5 stars$3.78+1.3%$5.50+45.5%+63.6%$191.87M$81.06M0.00210ARAYAccuray4.7051 of 5 stars$1.87+2.4%$9.00+380.3%-32.5%$188.47M$446.55M0.00987Analyst RevisionPROFProfound Medical2.4674 of 5 stars$7.42-3.5%$13.75+85.3%-31.2%$182.98M$7.20M0.00150Positive News Related Companies and Tools Related Companies IMAC Alternatives Anika Therapeutics Alternatives Pulmonx Alternatives Utah Medical Products Alternatives Perspective Therapeutics Alternatives Orchestra BioMed Alternatives InfuSystem Alternatives Sight Sciences Alternatives Accuray Alternatives Profound Medical Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BEAT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioTelemetry, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioTelemetry With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BEAT Stock Alerts